CXCR3 and neoplasm: Moreover, tumor‐bearing mice lacking the CXCL9 receptor CXCR3 show poor responses to anti‐PD1 treatment, suggesting that CXCL9 production by cDC1s is essential for facilitating the tumor immune response.